Stay updated with breaking news from Patient Centered. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deadline: 30-Apr-21 The U.S. Department of Health and Human Services (DHHS), Centers for Disease Control (CDC), invites eligible entities for its Health
/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, and...
Sirnaomics to Present at Medical Dermatology Summit News provided by Share this article , a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that it will be presenting results from a recently completed Phase 2a clinical study of the company's lead drug candidate, STP705, for treatment of squamous cell skin cancer, at the 19th Annual South Beach Symposium Medical Dermatology Summit. The virtual conference runs from Feb. 5-7, 2021. Title: Innovation in the Treatment of NMSC: siRNA STP705 for SCC in situ...
/PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic...
Search jobs 20-Dec-2020 Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced positive efficacy and safety results from a Phase 2a clinical study of the company's lead drug candidate, STP705, for treatment of squamous cell skin cancer. The open label, dose escalati...